News In!
doi: 10.1038/s41375-022-01573-6
Pardieu et al. Leukemia nominated cystine import as a druggable target in AML and raised the possibility to repurpose sulfasalazine for the treatment of AML, notably in combination with chemotherapy.
DOI.org/10.1182/blood.2021015328
Congratulations to Matthieu and his colleagues on the publication of a study in Blood. They showed that AML secondary to DDX41 germline mutations, the most common genetic predisposition in adult AML, have a specific biology, a good initial sensitivity to chemotherapy but frequent late relapses in the absence of stem cell transplantation.
January 2022
HAPPY 5th ANNIVERSARY!
Five years in and still counting :)
September 2021
The Puissant lab welcomes Giuseppe Di Feo, MD / PhD student INTERCEPT H2020, and Lois Kelly, PhD student iDEX Université de Paris, who have joined the lab for their thesis research. Welcome, Lois and Giuseppe!
June 2021
Congratulations to Alex Puissant on his new tenure-track position at INSERM (DR2)! Alex has started his faculty career at INSERM in 2016 as an Assistant Professor of Biology. Best wishes for a great career!
DOI:10.1126/scitranslmed.abg1168
Congratulations to Blandine, Camille, and their colleagues on the publication of a study in Science Translational Medicine. They conducted an in vivo screen to target non-oncogenic pathways essential for tumor survival and identified valosin-containing protein (VCP) as a stress-related vulnerability important for DNA repair in acute myeloid leukemia (AML).
September 2020
Raphael Itzykson was promoted to Professor of Hematology at Assistance Publique Hôpitaux de Paris. Raphael has started his faculty career at AP-HP in 2016 as an Assistant Professor of Adult Hematology. Congrats!
DOI:10.1158/2159-8290.CD-19-0970
Su et al. Cancer Discovery demonstrate that MTHFR and folate cycle deficiencies remodel the epigenetics landscape to shape transcriptional plasticity which represents a mechanism of resistance to MYC-targeting therapies.
DOI:10.1038/s41588-020-0590-9
Cancer cells know how to evolve and acquire resistance to conventional and targeted therapies. Lin et al. Nature Genetics have used chemogenomic screens to identify combination therapies that produce anticancer evolutionary traps, in which evading the first drug makes the cancer vulnerable to the second.
April 2019
Our team is on the cover of The INSERM Gazette (In vivo n°5). to present the ATIP-Avenir program of CNRS/Inserm for which Alex Puissant was laureate in 2016. This program is based on stringent and strictly objective evaluations by external experts of the young scientists in France, and is now being followed by related research organizations in other EU countries.
March 2019
Congratulations Alex for receiving the 24th Olga Sain Award from The Ligue Nationale Contre le Cancer for your very promising work on acute leukemia!
December 2018
As a laureate of the Young Researchers Bettencourt Prize in 2011, Alex Puissant has been invited along with Xavier Jeunemaître (1990), Béchir Jarraya (2006) and Marina Kvaskoff (2010), to share his story and explain how this prize can give momentum to a career and encourage to keep innovating in Sciences.
DOI: 10.1016/J.CMET.2018.11.009
Alex Puissant shares his reading of the article recently published by Kurmi et al. in Cell Metabolism, showing that HER2 signaling promotes ABL-mediated phosphorylation of the mitochondrial creatine kinase (MtCK1) to provide ATP and support breast tumor growth.
DOI:10.1182/BLOOD-2018-03-837781
Raphael Itzykson has discovered that the presence of multiple clones harboring muta-tions in the RTK/RAS pathway imparts an adverse prognosis in Core Binding Factor AML, while the presence of a single RTK/RAS clone has no impact on prognosis The Blood Journal.
January 2018
Among the best young researchers in life sciences, Alex Puissant has been selected by The Schlumberger Foundation for Education and Research (FSER) to support the creation of our lab, giving us the best chance to develop our work.
October 2017
Alex Puissant is laureate of the 2017 ERC Starting Grants that fund the top talented young researchers across Europe. This funding will enable us to set up our lab and pursue ground-breaking ideas from basic science to leukemia treatment.